WaveMan · Company
HLYK · Healthlynked Corp
> Search tickers & screens ⌘K
LIVE
← All companies

HLYK HealthLynked (HLYK) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-offices & clinics of doctors of medicine · CIK 0001680139
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
-31.3%
XBRL, annual
Net margin
-158.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.4M
four quarters, 2025-07-01 to 2026-06-30
History
FY Dec 2025$2.1M
FY Dec 2024$3.0M
FY Dec 2023$5.7M
FY Dec 2022$5.9M
FY Dec 2021$9.2M
Jun 2026$249.8K
Mar 2026$423.5K
Dec 2025$310.2K
Sep 2025$388.5K
Jun 2025$592.4K
Mar 2025$774.2K
Dec 2024$618.9K
Sep 2024$590.1K
At each fiscal year end
Single quarter
Net margin, TTM
-289.3%
net income over revenue, 2025-07-01 to 2026-06-30
History
FY Dec 2025-158.8%
FY Dec 2024-203.8%
FY Dec 2023-17.7%
FY Dec 2022-150.5%
FY Dec 2021-113.2%
Jun 2026n/a
Mar 2026-382.9%
Dec 2025-218.1%
Sep 2025-219.2%
Jun 2025-118.3%
Mar 2025-135.7%
Dec 2024-198.8%
Sep 2024-334.4%
At each fiscal year end
Single quarter
Free cash flow, TTM
-$1.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
History
FY Dec 2025-$1.7M
FY Dec 2024-$3.5M
FY Dec 2023n/a
FY Dec 2022-$4.4M
FY Dec 2021-$3.8M
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024-$743.6K
Sep 2024-$1.0M
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 20230.21x
FY Dec 20220.56x
FY Dec 20210.03x
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-8.56x
TTM operating cash flow over long-term 2023-03-31 (39 months older than the period end) plus current 2022-03-31 (51 months older than the period end)
History
FY Dec 2025-10.22x
FY Dec 2024-20.84x
FY Dec 2023-24.72x
FY Dec 2022-24.90x
FY Dec 2021-15.72x
Jun 2026-8.56x
Mar 2026-8.96x
Dec 2025-10.22x
Sep 2025-12.15x
Jun 2025-15.69x
Mar 2025-18.32x
Dec 2024-20.84x
Sep 2024-23.51x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023-180.9%
FY Dec 2022-234.5%
FY Dec 2021-243.5%
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-230.7%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-167.1%
FY Dec 2024-188.6%
FY Dec 2023-22.8%
FY Dec 2022-115.4%
FY Dec 2021-111.2%
Jun 2026-230.7%
Mar 2026-209.1%
Dec 2025-167.1%
Sep 2025-169.5%
Jun 2025-173.6%
Mar 2025-194.8%
Dec 2024-188.6%
Sep 2024-146.5%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023-279.2%
FY Dec 2022-175.2%
FY Dec 2021-89.4%
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024-787.4%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023770.00x
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$6.8M
market value at close 2026-10-09 on 2026-08-14 shares, plus long-term 2023-03-31 (39 months older than the period end) plus current 2022-03-31 (51 months older than the period end), minus cash 2026-06-30
History
FY Dec 2025$4.1M
FY Dec 2024$592.2M
FY Dec 2023$2.1B
FY Dec 2022$1.8B
FY Dec 2021$11.2B
Jun 2026$9.0M
Mar 2026$9.7M
Dec 2025$4.1M
Sep 2025$550.0M
Jun 2025$564.0M
Mar 2025$817.8M
Dec 2024$592.2M
Sep 2024$1.2B
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-21.6%
TTM free cash flow over market value at close 2026-10-09
History
FY Dec 2025-42.8%
FY Dec 2024-0.6%
FY Dec 2023n/a
FY Dec 2022-0.2%
FY Dec 2021-0.0%
Jun 2026-16.3%
Mar 2026-15.8%
Dec 2025-42.8%
Sep 2025-0.4%
Jun 2025-0.5%
Mar 2025-0.4%
Dec 2024-0.6%
Sep 2024-0.3%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

HLYK Stock Sonar score 3/7 axes

Find similar shapesCompare

HLYK ranks highest on risk and compliance (54th percentile) and growth (15th), and lowest on financial health (8th), among Healthcare Services peers.

Financial health
8
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-8.56x · 8 pct, sector of 66
Growth
15
Inputs
  • Revenue growth, YoY-31.3% · 7 pct, sector of 87
  • Backlog growth, YoY-15.8% · 23 pct, universe of 857
Risk and compliance
54
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 95
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+21.8% · 7 pct, sector of 71
4 not measured: Profitability, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
-31.3% year over year
below 93% of Healthcare Services
Margin
-158.8% net margin
below 96% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
the lowest in Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch HLYK

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+36.6%12M
-24%+75%+174%+273%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
NTRACSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSSERABDSX

HealthLynked insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for HealthLynked Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value
Rosal David
Chief Financial Officer
BUY
2024-06-24
28,333
$2.3K
Context
  • 1 earlier open-market trade here by this insider (1 buy), the last on Jun 20, 2024.
  • The trade is 45.7% of the 62,000 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Chief Financial Officer Rosal David bought about $2.3K of HLYK on the open market on Jun 24, 2024.
Rosal David
Chief Financial Officer
BUY
2024-06-20
33,667
$2.7K
Context
  • First open-market trade here by this insider on our record.
  • The trade is 100.0% of the 33,667 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Chief Financial Officer Rosal David bought about $2.7K of HLYK on the open market on Jun 20, 2024, the largest insider purchase at the company on our record.
2 transactions on record · a thin record, read with care
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns HLYK: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in HLYK

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

HLYK planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$2.1M$3.0M$5.7M$5.9M
Operating income$-2.1M$-4.7M$-4.2M$-8.7M
Net income$-3.3M$-6.1M$-1.0M$-8.8M
EPS (diluted)-1.16-2.180.00-0.04
Operating cash flow$-1.7M$-3.5M$-4.1M$-4.4M
Cash$37.1K$76.2K$247.2Kn/a
Long-term debtn/an/an/a$45.0K
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies